Characterization of 12 Unknown Photodegradation Impurities of Tunlametinib Capsules Using Liquid Chromatography Coupled With ion Trap/Time‐Of‐Flight Mass Spectrometry
Authors:
- 28 July 2025
- journal article
- Published by Wiley in Rapid Communications in Mass Spectrometry
- Vol. 39 (21) , e10113
Abstract
Rationale: In March 2024, tunlametinib capsules, a Class 1 new drug (referring to active pharmaceutical ingredients and formulations not previously marketed either nationally or globally), were approved in China for treating patients with advanced melanoma and neuroblastoma RAS viral oncogene homologue mutations who experienced disease progression or intolerance to anti‐PD‐1/PD‐L1 therapy. Risk assessment of impurity profiles is essential for drug safety and efficacy in clinical applications. This study characterized impurity profiles in tunlametinib capsules induced by photodegradation. Methods: Initial high‐performance liquid chromatography coupled with ion trap/time‐of‐flight mass spectrometry (HPLC/IT‐TOF MS) in positive ion mode was first performed to determine the m / z values of protonated ions and predict the formulas of the detected impurities. Subsequent LC‐MS n analyses ( n = 2–4) of target compounds elucidated comprehensive structural features. Results: Twelve previously unidentified photodegradation impurities in tunlametinib capsules were characterized using HPLC/IT‐TOF MS. Conclusions: Structural elucidation of 12 previously uncharacterized photodegradation impurities was achieved through HPLC/IT‐TOF MS. These findings establish a scientific foundation for refining quality specifications of tunlametinib.Keywords
This publication has 15 references indexed in Scilit:
- Forced Degradation Study of an Anti‐Diabetic Drug Imeglimin: Impurity Profiling and Structure Elucidation Using LC‐Q‐ToF‐MS/MS and NMRRapid Communications in Mass Spectrometry, 2024
- Tunlametinib: First ApprovalDrugs, 2024
- Targeted Therapy Innovations for MelanomaHematology/Oncology Clinics of North America, 2024
- Evolving cancer resistance to anti-PD-1/PD-L1 antibodies in melanoma: Comprehensive insights with future prospectsCritical Reviews in Oncology/Hematology, 2024
- A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanomaEuropean Journal of Cancer, 2024
- Degradation pathways and impurity profiling of the anticancer drug apalutamide by HPLC and LC–MS/MS and separation of impurities using Design of ExperimentsBiomedical Chromatography, 2022
- Characterization of unknown impurities in Coenzyme Q10 using LC–MS and NMRJournal of Pharmaceutical and Biomedical Analysis, 2019
- Separation and characterization of unknown impurities in cefonicid sodium by trap‐free two‐dimensional liquid chromatography combined with ion trap time‐of‐flight mass spectrometryRapid Communications in Mass Spectrometry, 2017
- Characterization of an unknown impurity in doxofylline using LC–MS and NMRJournal of Pharmaceutical and Biomedical Analysis, 2017
- Identification and characterization of process related impurities in chloroquine and hydroxychloroquine by LC/IT/MS, LC/TOF/MS and NMRJournal of Pharmaceutical and Biomedical Analysis, 2009